RT Journal Article
SR Electronic
T1 Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.21.21267898
DO 10.1101/2021.12.21.21267898
A1 Jacobsen, Henning
A1 Strengert, Monika
A1 Maaß, Henrike
A1 Ynga Durand, Mario Alberto
A1 Kessel, Barbora
A1 Harries, Manuela
A1 Rand, Ulfert
A1 Abassi, Leila
A1 Kim, Yeonsu
A1 Lüddecke, Tatjana
A1 Hernandez, Pilar
A1 Ortmann, Julia
A1 Heise, Jana-Kristin
A1 Castell, Stefanie
A1 Gornyk, Daniela
A1 Glöckner, Stephan
A1 Melhorn, Vanessa
A1 Kemmling, Yvonne
A1 Lange, Berit
A1 Dulovic, Alex
A1 Häring, Julia
A1 Junker, Daniel
A1 Schneiderhan-Marra, Nicole
A1 Hoffmann, Markus
A1 Pöhlmann, Stefan
A1 Krause, Gérard
A1 Cicin-Sain, Luka
YR 2022
UL http://medrxiv.org/content/early/2022/01/23/2021.12.21.21267898.abstract
AB SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-induced protection. The novel variant of concern (VoC) Omicron (B.1.1.529) has the largest number of amino acid alterations in its Spike protein to date. Thus, it may efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in convalescent and vaccinated individuals. We analyzed neutralization activity of sera from individuals after vaccination with all mRNA-, vector- or heterologous immunization schemes currently available in Europe by in vitro neutralization assay at peak response towards SARS-CoV-2 B.1, Omicron, Beta and Delta pseudotypes and also provide longitudinal follow-up data from BNT162b2 vaccinees. All vaccines apart from Ad26.CoV2.S showed high levels of responder rates (93-100%) towards SARS-CoV-2 wild-type, but some reductions in neutralizing Beta and Delta VoC pseudotypes. The novel Omicron variant had the biggest impact, both in terms of response rates and neutralization titers. Only mRNA-1273 showed a 100% response rate to Omicron and induced the highest level of neutralizing antibody titers, followed by heterologous prime-boost approaches. Homologous BNT162b2 vaccination or vector-based AZD1222 or Ad26.CoV2.S performed less well with peak responder rates of 33%, 50% and 9%, respectively. However, Omicron responder rates in BNT162b2 recipients were maintained in our six month longitudinal follow-up indicating that individuals with cross-protection against Omicron maintain it over time. Overall, our data strongly argues for urgent booster doses in individuals who were previously vaccinated with BNT162b2, or a vector-based immunization scheme.Competing Interest StatementNSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interest.Funding StatementThis work was financially supported by the Initiative and Networking Fund of the Helmholtz Association of German Research Centres through projects Virological and immunological determinants of COVID-19 pathogenesis: lessons to get prepared for future pandemics (KA1-Co-02 COVIPA) to LCS and grant number SO-96 to GK, by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germanys Excellence Strategy EXC 2155 RESIST Project ID 39087428 to LCS, and intramural funds of the Helmholtz Centre for Infection Research. SP was supported by BMBF (01KI2006D, 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK HZI COVID-19) and the German Research Foundation (DFG, PO 716/11-1, PO 716/14-1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Hannover Medical School (9086_BO_S_2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is provided with the manuscript. Additional data is available upon request from the corresponding authors.